These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34848157)

  • 1. Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands.
    Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Tascilar M; Mehra N; Lavalaye J; Somford DM; Aben KKH; Bergman AM; de Wit R; van den Bergh ACMF; de Groot CAU; Gerritsen WR
    Clin Genitourin Cancer; 2022 Feb; 20(1):43-52. PubMed ID: 34848157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
    Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
    Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
    Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
    Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.
    McKay R; Haider B; Duh MS; Valderrama A; Nakabayashi M; Fiorillo M; Ristovska L; Wen L; Kantoff P
    Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):276-282. PubMed ID: 28220804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
    Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
    Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
    Trieu J; Chang M; Rojas V; Varada N; Cao Y; Anderson M; Vogelzang NJ
    Clin Genitourin Cancer; 2022 Oct; 20(5):399-403. PubMed ID: 35680530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment patterns of castration-resistant prostate cancer in Japan, including symptomatic skeletal events and associated treatment and healthcare resource use.
    Uemura H; DiBonaventura M; Wang E; Ledesma DA; Concialdi K; Aitoku Y
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):511-517. PubMed ID: 28277852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
    Blas L; Shiota M; Matsumoto T; Hori Y; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
    Int J Urol; 2023 Nov; 30(11):1029-1034. PubMed ID: 37501328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry.
    Notohardjo JCL; Kuppen MCP; Westgeest HM; van Moorselaar RJA; Mehra N; Coenen JLLM; van Oort IM; de Vos AI; Vervenne WL; van den Bergh ACM; Aben KKH; Somford DM; Bergman AM; Uyl-de Groot CA; Gerritsen WR; van den Eertwegh AJM
    Eur Urol Focus; 2021 Jul; 7(4):788-796. PubMed ID: 32362484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
    Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.
    Clemons M; Ong M; Stober C; Ernst S; Booth C; Canil C; Mates M; Robinson A; Blanchette P; Joy AA; Hilton J; Aseyev O; Pond G; Jeong A; Hutton B; Mazzarello S; Vandermeer L; Kushnir I; Fergusson D;
    Eur J Cancer; 2021 Jan; 142():132-140. PubMed ID: 33023785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer.
    Sternberg CN; Saad F; Graff JN; Peer A; Vaishampayan UN; Leung E; Rosenbaum E; Gurney H; Epstein RJ; Davis ID; Wu B; Trandafir L; Wagner VJ; Hussain M
    Ann Oncol; 2020 Feb; 31(2):257-265. PubMed ID: 31959342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 study.
    Matsubara N; Kimura G; Uemura H; Uemura H; Nakamura M; Nagamori S; Mizokami A; Kikukawa H; Hosono M; Kinuya S; Krissel H; Siegel J; Kakehi Y
    Int J Clin Oncol; 2020 Apr; 25(4):720-731. PubMed ID: 31823152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
    Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
    Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
    Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Coenen JLLM; van den Bergh ACMF; Mehra N; Somford DM; Bergman AM; Ten Bokkel Huinink D; Fossion L; Geenen MM; Hendriks MP; van de Luijtgaarden ACM; Polee MB; Weijl NI; van de Wouw AJ; de Wit R; Uyl-de Groot CA; Gerritsen WR
    Eur Urol Oncol; 2021 Aug; 4(4):618-627. PubMed ID: 31601523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases.
    Blacksburg SR; Witten MR; Haas JA
    Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.